Vernal Sebastian, Brochado Maria Jose Franco, Bueno-Filho Roberto, Louzada-Junior Paulo, Roselino Ana Maria
Divisão de Dermatologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
Divisão de Imunologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
Rev Soc Bras Med Trop. 2018 Jan-Feb;51(1):99-104. doi: 10.1590/0037-8682-0216-2017.
Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE.
Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden's factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed.
Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation.
Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.
在多菌型（MB）麻风病中，皮质类固醇和/或沙利度胺与血栓栓塞事件（TBE）有关。本报告旨在确定与麻风病和TBE相关的基因和实验室特征。
评估抗磷脂抗体（aPL）、凝血相关检查、凝血酶原和莱顿因子V突变以及β2-糖蛋白-I（β2GPI）Val247Leu多态性。
7例麻风病患者中有6例在发生TBE期间接受了泼尼松和/或沙利度胺治疗，且至少有一项aPL呈阳性。所有患者均存在β2GPI多态性，1例出现凝血酶原突变。
皮质类固醇或沙利度胺的不良反应以及aPL和β2GPI多态性可能导致MB麻风病患者发生TBE。
